Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 23;10(11):1782.
doi: 10.3390/vaccines10111782.

Cellular and Humoral SARS-CoV-2 Vaccination Responses in 192 Adult Recipients of Allogeneic Hematopoietic Cell Transplantation

Thomas Meyer  1 , Gabriele Ihorst  2 , Ingrid Bartsch  1 , Robert Zeiser  1 , Ralph Wäsch  1 , Hartmut Bertz  1 , Jürgen Finke  1 , Daniela Huzly  3 , Claudia Wehr  1
Affiliations

Cellular and Humoral SARS-CoV-2 Vaccination Responses in 192 Adult Recipients of Allogeneic Hematopoietic Cell Transplantation

Thomas Meyer et al. Vaccines (Basel). .

Abstract

To determine factors influencing the vaccination response against SARS-CoV-2 is of importance in recipients of allogeneic hematopoietic cell transplantation (allo-HCT) as they display an increased mortality after SARS-CoV-2 infection, an increased risk of extended viral persistence and reduced vaccination response. Real-life data on anti-SARS-CoV-2-S1-IgG titers (n = 192) and IFN-γ release (n = 110) of allo-HCT recipients were obtained using commercially available, validated assays after vaccination with either mRNA (Comirnaty™, Pfizer-BioNTech™, NY, US and Mainz, Germany or Spikevax™, Moderna™, Cambridge, Massachusetts, US) or vector-based vaccines (Vaxzevria™,AstraZeneca™, Cambridge, UK or Janssen COVID-19 vaccine™Johnson/Johnson, New Brunswick, New Jersey, US), or after a heterologous protocol (vector/mRNA). Humoral response (78% response rate) was influenced by age, time after transplantation, the usage of antithymocyte globulin (ATG) and ongoing immunosuppression, specifically corticosteroids. High counts of B cells during the vaccination period correlated with a humoral response. Only half (55%) of participants showed a cellular vaccination response. It depended on age, time after transplantation, ongoing immunosuppression with ciclosporin A, chronic graft-versus-host disease (cGvHD) and vaccination type, with vector-based protocols favoring a response. Cellular response failure correlated with a higher CD8+ count and activated/HLA-DR+ T cells one year after transplantation. Our data provide the basis to assess both humoral and cellular responses after SARS-CoV2 vaccination in daily practice, thereby opening up the possibility to identify patients at risk.

Keywords: IFN-γ release assay (IGRA); SARS-CoV-2; allogeneic hematopoietic cell transplantation (allo-HCT); specific antibody titer.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

Figure 1
Figure 1
Humoral and cellular SARS-CoV-2 vaccination response. (A) Box plots display age at allo-HCT and the time from allo-HCT to best measured humoral (A) and cellular response (C) stratified according to responders and nonresponders. Points represent individual patients. (B,D) In the left column, pie charts show frequencies of usage of antithymocyte globulin (ATG), active ongoing treatment with immunosuppressants (ISP) and the usage of specific immunosuppressive agents in responders versus nonresponders. The right column displays frequencies of donor type, intensity of the conditioning chemotherapy and the vaccination protocol used in responders and nonresponders. Matched unrelated donors (MUD), matched related donors (MRD), mismatched unrelated donors (MMUD), mismatched related donors (MMRD), HLA-haploidentical donors (HAPLO), myeloablative conditioning (MAC), reduced toxicity myeloablative conditioning (RTC) and reduced intensity conditioning (RIC). Vaccination protocols displayed are based on only messenger RNA (mRNA) vaccines, only viral vector vaccines (V) or a heterologous combination of one-time viral vector vaccine followed by an mRNA vaccine (V + mRNA). *, p < 0.05.
See this image and copyright information in PMC

References

    1. Ljungman P., de la Camara R., Mikulska M., Tridello G., Aguado B., Zahrani M.A., Apperley J., Berceanu A., Bofarull R.M., Calbacho M., et al. COVID-19 and Stem Cell Transplantation; Results from an EBMT and GETH Multicenter Prospective Survey. Leukemia. 2021;35:2885–2894. doi: 10.1038/s41375-021-01302-5. - DOI - PMC - PubMed
    1. Sharma A., Bhatt N.S., St Martin A., Abid M.B., Bloomquist J., Chemaly R.F., Dandoy C., Gauthier J., Gowda L., Perales M.-A., et al. Clinical Characteristics and Outcomes of COVID-19 in Haematopoietic Stem-Cell Transplantation Recipients: An Observational Cohort Study. Lancet Haematol. 2021;8:e185–e193. doi: 10.1016/S2352-3026(20)30429-4. - DOI - PMC - PubMed
    1. Schaffrath J., Brummer C., Wolff D., Holtick U., Kröger N., Bornhäuser M., Kraus S., Hilgendorf I., Blau I.-W., Penack O., et al. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation—A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. Transplant. Cell. Ther. 2022;28:337.e1–337.e10. doi: 10.1016/j.jtct.2022.03.010. - DOI - PMC - PubMed
    1. Ghazy R.M., Ashmawy R., Hamdy N.A., Elhadi Y.A.M., Reyad O.A., Elmalawany D., Almaghraby A., Shaaban R., Taha S.H.N. Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Vaccines. 2022;10:350. doi: 10.3390/vaccines10030350. - DOI - PMC - PubMed
    1. Fendler A., Au L., Shepherd S.T.C., Byrne F., Cerrone M., Boos L.A., Rzeniewicz K., Gordon W., Shum B., Gerard C.L., et al. Functional Antibody and T Cell Immunity Following SARS-CoV-2 Infection, Including by Variants of Concern, in Patients with Cancer: The CAPTURE Study. Nat. Cancer. 2021;2:1321–1337. doi: 10.1038/s43018-021-00275-9. - DOI - PubMed